Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KK3910 in Healthy Volunteers and Patients With Essential Hypertension
NCT06823947Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in essential hypertension comparing Placebo with KK3910 (2 arms). Primary endpoint: Number of participants with adverse events at Day 155. Started Apr 2025; status: recruiting.
02
Drugs
KK3910
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT06823947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823947.